Abstracts tagged "lupus nephritis and proteomics"

Abstract Number: 100 • 2018 ACR/ARHP Annual Meeting
Glycosphingolipids and Proteins in Urine Exosomes: Potential Biomarkers of Lupus Nephritis
Tamara K. Nowling¹, Jessalyn Rodgers¹, Jim C. Oates², Michael Janech³ and Richard Drake⁴, ¹Medicine/Rheumatology, Medical University of South Carolina, Charleston, SC, ²Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Medicine/Nephrology, Medical University of South Carolina, Charleston, SC, ⁴Pharmacology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Exosomes, extracellular vesicles that are abundant in human urine and contain proteins from renal cells, are a potential source of biomarkers of renal disease…
Abstract Number: 722 • 2015 ACR/ARHP Annual Meeting
Biomarkers/Pathways Discovery of Lupus Nephritis By Urine Proteomics
Michelle Petri¹, Wei Fu², Adnan Kiani¹, Lauren DeVine¹, Conover Talbot Jr.¹ and Robert Cole¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: We have previously validated several urine proteomic biomarkers for Lupus Nephritis (osteoprotegerin, MCP-1, VCAM-1 and urine TWEAK). In this discovery effort we looked for…
Abstract Number: 3083 • 2015 ACR/ARHP Annual Meeting
Antibody Array Based Proteomic Screening of 274 Serum Markers in Systemic Lupus Erythematosus
Tianfu Wu¹, Huihua Ding², Cristina Arriens³, Chungwen Wei⁴, Jennifer H. Anolik⁵, David R. Karp³, Nancy J. Olsen⁶, Michelle Petri⁷, Ignacio Sanz⁴, Ramesh Saxena⁸ and Chandra Mohan², ¹Department of Biomedical Engineering, University of Houston, Houston, TX, ²Biomedical Engineering, University of Houston, Houston, TX, ³Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁴Rheumatology, Emory University, Atlanta, GA, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Divsion of Rheumatology, Department of Medicine, Penn State MS Hershey Medical Center, Hershey, PA, ⁷Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁸Nephrology, University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Given that early detection of renal involvement in systemic lupus erythematosus (SLE) and prompt management of the disease can have a significant impact on…
Abstract Number: 91 • 2014 ACR/ARHP Annual Meeting
Quantitative Proteomics Using Dimethyl Isotope Labeling for Comparison of Fresh Frozen Versus Formalin-Fixed, Paraffin-Embedded Tissue for Lupus Nephritis
Abhimanyu Amarnani¹, Joseph Capri², Puneet Souda³, David Elashoff⁴, Ivan Lopez⁵, Julian Whitelegge³ and Ram Singh¹, ¹Medicine/Rheumatology, University of California, Los Angeles, Los Angeles, CA, ²Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, ³The Pasarow Mass Spectrometry Laboratory, University of California, Los Angeles, Los Angeles, CA, ⁴Medicine/Statistics Core, University of California, Los Angeles, Los Angeles, CA, ⁵Head and Neck Surgery, University of California, Los Angeles, Los Angeles, CA
Background/Purpose Lupus nephritis (LN) progresses from mild focal inflammation, to diffuse proliferative nephritis, to fibrosis and end-stage renal disease. Though the understanding of LN has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].